Table 3.

Comparison of the Total Scores between Takayasu Arteritis and Giant Cell Arteritis for 21 Vessels

	Total, n = 51	TAK, n = 24	GCA, n = 27	P
Wall thickening before treatment, median (IQR)	6 (4-13)	8 (5-12.5)	5 (3-15)	.289
Wall thickening after treatment, median (IQR)	2 (0-5)	4 (2-7)	1 (0-3)	.003
Wall enhancement before treatment, median (IQR)	4 (2-8)	3 (2-8)	5 (1-9)	.609
Wall enhancement after treatment, median (IQR)	0 (0-2)	1 (0-4)	0 (0-0)	.005
Total of acute-phase findings before treatment, median (IQR)	11 (6-20)	11.5 (6-20)	9 (4-25)	.610
Total of acute-phase findings after treatment, median (IQR)	2 (0-8)	6.5 (2-10.5)	1 (0-4)	.003
Stenosis, occlusion before treatment, median (IQR)	0 (0-2)	1 (0-2.7)	0 (0-0)	.004
Stenosis, occlusion after treatment, median (IQR)	0 (0-2)	2 (0-3)	0 (0-1)	.009
Dilatation, aneurysm before treatment, median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	.320
Dilatation, aneurysm after treatment, median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	.395
Calcification before treatment, median (IQR)	1 (0-5)	0 (0-0)	4 (2-7)	<.0001
Calcification after treatment, median (IQR)	0 (0-5)	0 (0-0)	4 (2-7)	<.0001
Total of chronic-phase findings before treatment, median (IQR)	3 (1-6)	1.5 (0-3.7)	5 (3-9)	<.0001
Total of chronic-phase findings after treatment, median (IQR)	4 (2-6)	2 (0-4)	6 (4-9)	.001

Data were analysed using the Mann–Whitney U-test. The P values are calculated for the differences between TAK and GCA. Acute-phase findings include a combination of wall thickening and contrast enhancement of the vascular wall. Chronic-phase findings include a combination of stenosis, occlusion, dilatation, aneurysm, and calcification.

GCA, giant cell arteritis; IQR, interquartile range; TAK, Takayasu arteritis.